Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 1045-1049, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallemacq, P. E.
Right arrow Articles by Hassoun, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallemacq, P. E.
Right arrow Articles by Hassoun, A.

Clinical Chemistry, Vol 39, 1045-1049, Copyright © 1993 by American Association for Clinical Chemistry

Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours

PE Wallemacq, I Firdaous and A Hassoun
Laboratoire de Toxicologie et de Monitoring Therapeutique, Cliniques Universitaires St. Luc, Bruxelles, Belgique.

FK506, a promising new immunosuppressant, is currently under clinical investigation. Because dose-dependent toxicity is possible, blood concentrations of FK506 should be monitored. We improved the original ELISA of FK506 by shortening the incubation time. With some modification of materials, results are obtained within 6 h instead of 2 days, with similar or even better precision. Internal and external quality-control programs showed that our results correlated satisfactorily both with values determined by the original method and the theoretical expected values. Either plasma (detection limit 0.1 microgram/L) or whole-blood (detection limit 1 microgram/L) samples can be used. The sensitivity of the method makes it particularly useful for accurate pharmacokinetic studies or measurement of low blood concentrations. Twenty-four drugs and nine biological variables showed no significant interference on the assay. Study of the concentration- and temperature-dependent distribution of FK506 shows that the drug is largely bound to erythrocytes (ratio of blood to plasma concentrations is 10-40); as the erythrocytes become saturated, more of the drug is found in the plasma. Plasma concentrations may vary according to the blood temperature. We conclude that whole blood should be used for FK506 monitoring, as it is for monitoring cyclosporine.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. L. Cogill, P. J. Taylor, I. S. Westley, R. G. Morris, S. V. Lynch, and A. G. Johnson
Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients
Clin. Chem., September 1, 1998; 44(9): 1942 - 1946.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. E. Wallemacq, T. Leal, T. Besse, J.-P. Squifflet, R. Reding, J.-B. Otte, J. Lerut, and A. Hassoun
IMx Tacrolimus II vs IMx Tacrolimus Microparticle Enzyme Immunoassay Evaluated in Renal and Hepatic Transplant Patients
Clin. Chem., October 1, 1997; 43(10): 1989 - 1991.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.